PMS-SACUBITRIL-VALSARTAN DIN 02564440
Status: Marketed
Holder: PHARMASCIENCE INC
Health Canada record
| Active ingredient(s) | SACUBITRIL (SACUBITRIL VALSARTAN SODIUM COMPLEX) 49 MG; VALSARTAN (SACUBITRIL VALSARTAN SODIUM COMPLEX) 51 MG |
|---|
| Dosage form | Tablet |
|---|
| Route | Oral |
|---|
| Schedule | PRESCRIPTION |
|---|
| Class | Human |
|---|
| ATC | C09DX04 VALSARTAN AND SACUBITRIL |
|---|
| Original market date | 22-Jan-2026 |
|---|
| Current status date | 22-Jan-2026 |
|---|
| Source | Health Canada DPD |
|---|
Establishment licence of the holder
Pharmascience Inc. — licence 100241, currently licensed, last inspection rating C (2025-03-20).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing SACUBITRIL (SACUBITRIL VALSARTAN SODIUM COMPLEX)
| DIN | Product | Company | Form | Strength | Status |
|---|
| 02564432 | PMS-SACUBITRIL-VALSARTAN | PHARMASCIENCE INC | Tablet | SACUBITRIL (SACUBITRIL VALSARTAN SODIUM COMPLEX) 24 MG; VALSARTAN (SACUBITRIL VALSARTAN SODIUM COMPLEX) 26 MG | Marketed |
| 02564459 | PMS-SACUBITRIL-VALSARTAN | PHARMASCIENCE INC | Tablet | SACUBITRIL (SACUBITRIL VALSARTAN SODIUM COMPLEX) 97 MG; VALSARTAN (SACUBITRIL VALSARTAN SODIUM COMPLEX) 103 MG | Marketed |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|
| 36729 | 2026-01-13 | Abbreviated New Drug Submission (ANDS) | |
Request a quote for PMS-SACUBITRIL-VALSARTAN
How to read a Canadian DIN record